evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,756 questions · 13,493 findings · 1,305 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 2,594 · 19.2%GRADE not reported 728 · 5.4%Very low 2,868 · 21.3%Low 3,777 · 28%Moderate 2,620 · 19.4%High 906 · 6.7%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Rituximab vs placebo

Common infections measured by clinical assessment over 28 months · primary progressive multiple sclerosis

Rituximab as 'first choice' showed no clear difference in common infections measured by clinical assessment over 28 months compared with placebo (low certainty).

1 finding from 1 review

Rituximab vs placebo

Cancer · primary progressive multiple sclerosis

Rituximab as 'first choice' showed no clear difference in cancer measured by clinical assessment over 28 months compared with placebo (low certainty).

1 finding from 1 review

Rituximab vs placebo

Mortality measured by clinical assessment over 12 months · primary progressive multiple sclerosis

Rituximab as 'first choice' showed no clear difference in mortality measured by clinical assessment over 28 months compared with placebo (low certainty).

1 finding from 1 review

Rituximab vs placebo

Clinical relapse · relapsing multiple sclerosis

Rituximab as 'switching' may leads to lower relapse measured by clinical assessment over 12 months compared with placebo (low certainty).

1 finding from 1 review

Rituximab vs placebo

Serious adverse events measured by clinical assessment over 12 months · relapsing multiple sclerosis

It is very uncertain whether rituximab as 'switching' changes serious adverse events measured by clinical assessment over 12 months compared with placebo (very low certainty).

1 finding from 1 review

Rituximab vs placebo

Common infections measured by clinical assessment over 12 months · relapsing multiple sclerosis

It is very uncertain whether rituximab as 'switching' changes common infections measured by clinical assessment over 12 months compared with placebo (very low certainty).

1 finding from 1 review

Rituximab vs placebo

Cancer · relapsing multiple sclerosis

It is very uncertain whether rituximab as 'switching' changes cancer measured by clinical assessment over 12 months compared with placebo (very low certainty).

1 finding from 1 review

Rituximab vs placebo

Mortality measured by clinical assessment over 12 months · relapsing multiple sclerosis

It is very uncertain whether rituximab as 'switching' changes mortality measured by clinical assessment over 12 months compared with placebo (very low certainty).

1 finding from 1 review

Rituximab vs placebo

Disability worsening · primary progressive multiple sclerosis

Rituximab as 'first choice' showed no clear difference in disability worsening measured by EDSS over 24 months compared with placebo (moderate certainty).

1 finding from 1 review

Rituximab vs placebo

Clinical relapse · primary progressive multiple sclerosis

Rituximab as 'first choice' showed no clear difference in relapse measured by clinical assessment over 24 months compared with placebo (low certainty).

1 finding from 1 review

Rituximab vs placebo

Serious adverse events measured by clinical assessment over 12 months · primary progressive multiple sclerosis

Rituximab as 'first choice' showed no clear difference in serious adverse events measured by clinical assessment over 28 months compared with placebo (low certainty).

1 finding from 1 review

Oral misoprostol vs placebo/no treatment

Uterine hyperstimulation with fetal heart rate changes · women with ruptured membranes in the third trimester for induction of labour.

It is very uncertain whether oral misoprostol changes uterine hyperstimulation with fetal heart rate changes compared with placebo/no treatment (very low certainty).

1 finding from 1 review

Oral misoprostol vs placebo/no treatment

Uterine hyperstimulation without fetal heart rate changes · women with ruptured membranes in the third trimester for induction of labour.

It is very uncertain whether oral misoprostol changes uterine hyperstimulation without fetal heart rate changes compared with placebo/no treatment (very low certainty).

1 finding from 1 review